Claims for Patent: 10,239,927

Summary for Patent: 10,239,927

Title:	Peptides and compositions for treatment of joint damage
Abstract:	The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.
Inventor(s):	Johnson; Kristen (San Diego, CA), Shi; Jian (San Diego, CA)
Assignee:	Novartis AG (Basel, CH)
Application Number:	15/660,914
Patent Claims:	1. A method of treating or ameliorating arthritis or articular cartilage damage in a subject, the method comprising administering to a joint of the subject a therapeutically effective amount of a polypeptide comprising SEQ ID NO: 28. 2. The method of claim 1, wherein the subject has arthritis, and wherein the arthritis is osteoarthritis, trauma arthritis, or autoimmune arthritis. 3. The method of claim 1, further comprising administering to the subject one or more additional chondrogenic factors. 4. The method of claim 1, further comprising administering to the subject hyaluronic acid or a derivative thereof. 5. The method of claim 1, further comprising administering to the subject an agent selected from the group consisting of oral salmon calcitonin, SD-6010 (iNOS inhibitor), vitamin D3 (choliecalciferol), collagen hydrolyzate, FGF18, BMP7, rusalatide acetate, avocado soy unsaponifiables (ASU), kartogenin, a steroid, and a non-steroidal anti-inflammatory agent (NSAID). 6. The method of claim 1, further comprising performing a surgical procedure on an affected joint in a subject. 7. The method of claim 6, wherein administering the polypeptide occurs during or after the surgical procedure. 8. The method of claim 1, wherein administering the polypeptide occurs in conjunction with any one of bone marrow stimulation, cartilage replacement, autologous chondrocyte implantation (ACI), matrix-induced autologous chondrocyte implantation (MACI). 9. The method of claim 1, wherein administering the polypeptide occurs in conjunction with autologous chondrocyte implantation (ACI). 10. The method of claim 1, wherein the polypeptide is administered in a matrix or biocompatible scaffold. 11. The method of claim 1, further comprising determining the expression level of a hyaline cartilage-specific protein in the joint before and after administering the polypeptide, wherein the hyaline cartilage-specific protein is type II collagen or aggrecan. 12. The method of claim 11, wherein the expression level of the hyaline cartilage-specific protein is determined by immunohistochemistry, immunocytochemistry, or PCR. 13. The method of claim 1, further comprising determining the expression level of a fibrotic cartilage-specific protein in the joint before and after administering the polypeptide, wherein the fibrotic cartilage-specific protein is type X collagen. 14. The method of claim 13, wherein the expression level of the fibrotic cartilage-specific protein is determined by immunohistochemistry, immunocytochemistry, or PCR. 15. A method of inducing differentiation of mesenchymal stem cells into chondrocytes, the method comprising contacting mesenchymal stem cells with an effective amount of a polypeptide comprising SEQ ID NO: 28. 16. The method of claim 15, wherein the method is performed in vivo and the stem cells are present in a human subject. 17. The method of claim 16, wherein the subject has arthritis or cartilage damage. 18. The method of claim 17, wherein the arthritis is osteoarthritis, trauma arthritis, or autoimmune arthritis. 19. The method of claim 16, further comprising administering to the subject one or more additional chondrogenic factors. 20. The method of claim 16, further comprising administering to the subject an agent selected from the group consisting of hyaluronic acid or a derivative thereof, oral salmon calcitonin, SD-6010 (iNOS inhibitor), vitamin D3 (choliecalciferol), collagen hydrolyzate, FGF18, BMP7, rusalatide acetate, avocado soy unsaponifiables (ASU), kartogenin, a steroid, and a non-steroidal anti-inflammatory agent (NSAID).

Details for Patent 10,239,927

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Vericel Corporation	MACI	autologous cultured chondrocytes on porcine collagen membrane	Cell Sheets	125603	12/13/2016		2039-10-24